Skip to main content

A sensitive method to quantify human cell-free circulating DNA in blood: Relevance to myocardial infarction screening.

Jing RR, Wang HM, Cui M, Fang MK, Qiu XJ, Wu XH, Qi J, Wang YG, Zhang LR, Zhu JH, Ju SQ

Publication: Clin Biochem (2011) • Vol 44 • Page 1074-9PMID: 21723272View on PubMed

Purpose

The purpose of this paper was to evaluate a new method of quantifying cell free circulating DNA (cf-DNA) to aid in the diagnosis of myocardial infarction (MI).

Conclusion

Serum had more cf-DNA than EDTA plasma. Males had significantly lower levels of cf-DNA in serum than females. The levels of cf-DNA were much higher in the plasma of patients with MI than in normal controls. There was no correlation of cf-DNA levels with creatine kinase-MB (CK-MB), troponin I (cTnI), or myoglobin (MYO).

Studies (1)

Purpose

The purpose of this study was to determine the effects of blood component, gender, and diagnosis of MI on cf-DNA levels in blood. Blood was separated after collection and then frozen at -80 degrees C until all specimens were obtained. Serum was collected in serum separator tubes (SST).

Summary of Findings

Serum had more cf-DNA than EDTA plasma. There was insignificantly lower cf-DNA in EDTA plasma from males than females (p>0.05), but males had significantly lower levels of cf-DNA in serum than females (mean 154.6 versus 255.8 ng/mL, P<0.05). The levels of cf-DNA were much higher in the plasma of patients with MI than in normal controls (median of 4439.4 and 117.6 ng/mL, respectively). There was no correlation of cf-DNA levels with CK-MB, cTnI, or MYO. In serially collected specimens, cf-DNA peaked before cTnI. The assay was able to accurately quantify cf-DNA at concentrations of 20-400 ng/mL with a coefficient of variance of 13.04, 7.54, and 7.53 for 20 ng/mL, 100 ng/mL and 200 ng/mL, respectively.

  • Biospecimens

    FluidPlasma
    FluidSerum
    FluidBlood
  • Preservation Types

    Frozen
  • Diagnoses

    Normal
    Cardiovascular Disease
  • Platforms

    DNABranch DNA assay
    ProteinImmunoassay
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Myocardial infarct
    Normal
    PreaquisitionPatient gender
    Female
    Male
    Biospecimen AcquisitionTime of biospecimen collection
    After angioplasty
    At admission
    Before angioplasty
    Biospecimen Aliquots and ComponentsBlood and blood products
    Plasma
    Serum
    Immunoassay SpecificTargeted peptide/protein
    Creatine kinase-MB
    Myoglobin
    Troponin 1